Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This case series reports two adolescent males with anti-CASPR2-positive Morvan syndrome, negative malignancy screening, and complete six-month clinical remission after carbamazepine, pulse methylprednisolone, and intravenous immunoglobulin.
The reported remissions support, but do not establish, that early immunotherapy combined with symptomatic membrane-stabilizing treatment may reverse adolescent anti-CASPR2-associated Morvan syndrome; any relevance to pediatric oncology is indirect because both malignancy screenings were negative.
In three pediatric patients with medulloblastoma or pineoblastoma, rapid post-proton-CSI total-body PET/CT visualized irradiation-associated activity across the craniospinal axis and its time-dependent redistribution and decline throughout the body.
The study directly supports the feasibility of dynamic total-body imaging after proton craniospinal irradiation; it is an inference, not demonstrated here, that this approach could eventually aid treatment verification, workflow optimization, or assessment of proton-induced activity and washout.
In a nationwide retrospective cohort of 143 Danish children with neuroblastoma, 30% had musculoskeletal symptoms and 12% had prior musculoskeletal misdiagnoses, which were associated with hospital-related diagnostic delay and more advanced disease but not significantly different adjusted survival.
The evidence identifies back pain and arthralgia as potential diagnostic red flags; it is an untested inference that heightened clinical suspicion or earlier abdominal ultrasound in children with unexplained musculoskeletal symptoms could shorten diagnostic delay and improve care or outcomes.
This multicenter observational study of 83 pediatric cancer patients found that an ePRO platform incorporating a serious game was generally usable and feasible, but engagement declined over time and varied with age and health care professional involvement.
The study provides evidence that pediatric ePRO collection is feasible and that acknowledgment by health care professionals may motivate reporting; it is reasonable—but not demonstrated—to hypothesize that age-tailored content, timely clinical feedback, and workflow integration could improve symptom monitoring, communication, and ultimately supportive or palliative care outcomes.
This retrospective five-patient MEN2B case series reports that infant or early-childhood extra-endocrine manifestations—including chronic constipation, congenital clubfoot, and alacrimia—prompted RET testing and diagnosis before or near endocrine disease onset, enabling timely surgical management.
The reported cases support early recognition of characteristic extra-endocrine features as a trigger for RET testing; it is plausible, but not established by this uncontrolled series, that this pathway could enable thyroidectomy before metastatic medullary thyroid carcinoma and thereby improve outcomes.
This single-center retrospective study found that 111 surgically or pathologically confirmed pediatric secondary intussusceptions had lead-point-specific age, sex, imaging, enema-response, necrosis, and recurrence patterns, with lymphoma among five evaluated etiologies.
The reported associations support using age, recurrence, ultrasound findings, and enema response to raise suspicion for pathological lead points; it remains an inference requiring prospective validation that a multiparameter model could identify lymphoma or other etiologies earlier and improve treatment selection or outcomes.
This review synthesizes clinical and preclinical literature suggesting that cancer cachexia is associated with bone loss and skeletal fragility beyond metastasis or treatment-induced bone loss, including potential osteosarcopenia in adult and pediatric cancers.
The supplied record supports cachexia-associated skeletal deterioration as an underrecognized clinical problem; it remains an inference, not a demonstrated intervention result, that cachexia-directed therapy, bone-protective treatment, or enhanced musculoskeletal screening could reduce osteoporosis and fractures or improve outcomes.
In a retrospective Thai multicenter cohort of 50 predominantly older adults with unresectable or advanced hepatocellular carcinoma, durvalumab plus tremelimumab produced a 12% objective response rate, median overall survival of 10.5 months, and grade ≥3 adverse events in 24%, with broadly similar outcomes in the 43 HIMALAYA-eligible patients.
The record provides observational evidence that durvalumab plus tremelimumab can have antitumor activity with manageable reported toxicity in routine adult HCC practice; it may support use or further study in appropriately selected adults, but any relevance to pediatric liver cancer is unsupported and purely inferential.
This retrospective five-patient series, including one adolescent, reports prolonged recurrence-free follow-up after gross total endoscopic resection of localized nasal skull-base Rosai-Dorfman disease, while a partially resected lesion required repeat surgery after limited symptomatic response to postoperative methylprednisolone.
The reported observations support maximal safe endoscopic resection as a potentially effective local treatment for anatomically resectable nasal skull-base RDD; however, comparative benefit, pediatric applicability, safety, and the added value of postoperative corticosteroids remain unproven.
The study models annual pediatric ALL medicine requirements and a combined national pharmaceutical budget of IDR 5.91 billion in Indonesia, identifying L-asparaginase, induction therapy, and a small set of drug–risk-group combinations as the principal cost drivers.
Evidence: morbidity-based modeling identifies medicines and treatment phases that dominate projected pediatric ALL spending; inference: using these estimates for risk-specific procurement and budgeting could reduce medicine shortages or interruptions and thereby improve treatment access, but the record provides no evidence that implementation improves clinical outcomes.
The paper reports the establishment of SEHOP-PENCIL, a Spanish multicenter precision-oncology network that standardizes genomic evaluation and national molecular tumor-board review for children, adolescents, and young adults with cancer while addressing identified disparities in sequencing access.
The record supports that SEHOP-PENCIL may broaden and standardize access to molecular diagnosis and treatment-selection discussions; it is an inference—not demonstrated here—that this infrastructure will increase matched-therapy use, reduce disparities, or improve patient outcomes.
In a nationwide register-based cohort, family history increased absolute colorectal cancer incidence similarly among patients with IBD and matched comparators, with the largest increase in individuals with at least two affected first-degree relatives rather than those defined only by early-onset CRC heredity.
The observational evidence suggests that the number of affected first-degree relatives may improve CRC risk stratification in IBD; it is an untested inference that prioritizing such patients for intensified surveillance would improve early detection or outcomes, particularly in pediatric-onset IBD.
